RAMM Pharma (RAMM) Stock Overview
Operates in the pharmaceutical and medical product business in Uruguay and Poland. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
RAMM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
RAMM Pharma Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.02 |
| 52 Week High | CA$0.25 |
| 52 Week Low | CA$0.01 |
| Beta | 0.63 |
| 1 Month Change | 33.33% |
| 3 Month Change | -50.00% |
| 1 Year Change | 33.33% |
| 3 Year Change | -76.47% |
| 5 Year Change | -98.00% |
| Change since IPO | -96.97% |
Recent News & Updates
Shareholder Returns
| RAMM | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | 1.3% |
| 1Y | 33.3% | 54.9% | 44.6% |
Return vs Industry: RAMM underperformed the Canadian Pharmaceuticals industry which returned 50.5% over the past year.
Return vs Market: RAMM underperformed the Canadian Market which returned 41.1% over the past year.
Price Volatility
| RAMM volatility | |
|---|---|
| RAMM Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 11.0% |
| Market Average Movement | 11.0% |
| 10% most volatile stocks in CA Market | 19.2% |
| 10% least volatile stocks in CA Market | 3.9% |
Stable Share Price: RAMM's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: Insufficient data to determine RAMM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | Jack Burnett | www.wearerammpharma.com |
RAMM Pharma Corp., together with its subsidiaries, operates in the pharmaceutical and medical product business in Uruguay and Poland. The company offers cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other cannabis-based products; and pharmaceuticals, cosmetics, and nutraceutical products. It also engages in the resale of medical supplies products; and the sale of medical devices and consumables.
RAMM Pharma Corp. Fundamentals Summary
| RAMM fundamental statistics | |
|---|---|
| Market cap | CA$2.39m |
| Earnings (TTM) | -CA$8.65m |
| Revenue (TTM) | CA$2.56m |
Is RAMM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RAMM income statement (TTM) | |
|---|---|
| Revenue | CA$2.56m |
| Cost of Revenue | CA$1.80m |
| Gross Profit | CA$761.57k |
| Other Expenses | CA$9.41m |
| Earnings | -CA$8.65m |
Last Reported Earnings
Jan 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.072 |
| Gross Margin | 29.71% |
| Net Profit Margin | -337.31% |
| Debt/Equity Ratio | 0% |
How did RAMM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/10 08:37 |
| End of Day Share Price | 2026/04/07 00:00 |
| Earnings | 2026/01/31 |
| Annual Earnings | 2025/10/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
RAMM Pharma Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.